A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients

Diffuse Large B-Cell Lymphoma, Unspecified Site Clinical Trial

Official title: A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated Diffuse Large B-cell Lymphoma (DLBCL) Patients

Status Recruiting

Clinical Trial Summary

A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated Diffuse Large B-cell Lymphoma (DLBCL) Patients

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Diffuse Large B-Cell Lymphoma, Unspecified Site
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse

• NCT number: NCT03650933
• Study type: Interventional
• Source: Nanjing Yoko Biomedical Co., Ltd.
• Contact: Tie Xu, Master
• Phone: 86-18036618680
• Email: xutie@yoko-bio.com
• Status: Recruiting
• Phase: Phase 3
• Start date: December 28, 2018
• Completion date: December 31, 2025